FDA to Hold Final Assessment of the Program for Enhanced Review Transparency and Communication in the Biosimilar User Fee Act | Goodwin
Tomorrow, March, 22, 2022, the FDA will host a public meeting entitled “Final Assessment of the Program for Enhanced Review Transparency and Communication in in the Biosimilar User Fee...
Program In Bs Communication The Program Eastern Research Group Inc Program For Enhanced Enhanced Review Transparency Biosimilar User Fee Act
Source: jdsupra.com